Senhwa Biosciences’ Pidnarulex joins forces with global PD-1 leaders to advance next-gen immunotherapy

This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program

Rona submits IND for GalNAc-conjugated siRNA targeting obesity

RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options

Atom enrolls first patient in global phase 2 trial of ABP-745 for acute gout flares

ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases

Biostar Pharma doses first patient in Phase II/III multiregional trials of utidelone capsule

Ascletis' ASC30 obesity drug shows 75-day half-life in US Study

Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity

Novo Nordisk survey finds Wegovy reduces food noise and improves mental well-being in people with obesity

The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy

Brenntag expands partnership with Lallemand to deliver Nutrilife baking enzymes across North America

Brenntag will supply Food & Nutrition customers in the United States and Canada with Lallemand’s renowned Nutrilife baking enzyme range

Libtayo plus chemotherapy demonstrates five-year survival benefit in advanced NSCLC

Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone

MoS Health Patel inaugurates National Virus Research & Diagnostic Laboratory Conclave 2025

Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem

Advent to sell generic drugmaker Zentiva to GTCR

Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business